Nacimbio (also wrote as Natsimbio), or OJSC National Immunobiological Company, is a subsidiary of the Rostec state corporation in Russia and was established in 2013 as a part of an effort by the Government of Russia to achieve independence in the production of pharmaceutical products, particularly those for the treatment of communicable diseases. Ownership Nacimbio is a state owned enterprise in Russia, with Rostec holding a 75% stake in the company, with the remaining 25% stake owned by Russian investment firm Marathon group. Products The company focuses on developing productsin 5 key areas of the Pharmaceuticals sector: Vaccines, Tuberculosis, HIV and hepatitis, haematology and insulin. In addition to this, the company has recently begun development on a combined Flu and Coronavirus vaccine. Subsidiaries -NGO "Microgen" -"FORT" -"Synthesis" -MPO Metalist The company also holds a 37% stake in Kirov Plasma. References